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Abstract: Background
Limited data exists on the impact of COVID-19 on national changes in cardiac
procedure activity, including patient characteristics and clinical outcomes before and
during the COVID-19 pandemic.
Methods and Results
All major cardiac procedures (n=374,899) performed between 1st  January and 31st
May for the years 2018, 2019 and 2020 were analysed, stratified by procedure type
and time-period (pre-COVID:January-May 2018 and 2019 and January-February
2020; COVID:March-May 2020). Multivariable logistic regression was performed to
examine the odds ratio (OR) of 30-day mortality for procedures performed in the
COVID period.
Overall, there was a deficit of 45,501 procedures during the COVID period compared to
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
the monthly averages (March-May) in 2018-2019. Cardiac catheterisation and device
implantations were the most affected in terms of numbers (n=19,637 and n=10,453)
whereas surgical procedures such as MVR, other valve replacement/repair, ASD/VSD
repair and CABG were the most affected as a relative percentage difference (Δ) to
previous years’ averages. TAVR was the least affected (Δ-10.6%). No difference in 30-
day mortality was observed between pre-COVID and COVID time-periods for all
cardiac procedures except cardiac catheterisation (OR 1.25 95% confidence interval
(CI) 1.07-1.47, p=0.006) and cardiac device implantation (OR 1.35 95% CI 1.15-1.58,
p<0.001).
Conclusion
Cardiac procedural activity has significantly declined across England during the
COVID-19 pandemic, with a deficit in excess of 45000 procedures, without an increase
in risk of mortality for most cardiac procedures performed during the pandemic. Major
restructuring of cardiac services is necessary to deal with this deficit, which would
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Background: Limited data exists on the impact of COVID-19 on national changes in cardiac 
procedure activity, including patient characteristics and clinical outcomes before and during 
the COVID-19 pandemic.  
Methods and Results: All major cardiac procedures (n=374,899) performed between 1st 
January and 31st May for the years 2018, 2019 and 2020 were analysed, stratified by procedure 
type and time-period (pre-COVID: January-May 2018 and 2019 and January-February 2020 
and COVID: March-May 2020). Multivariable logistic regression was performed to examine 
the odds ratio (OR) of 30-day mortality for procedures performed in the COVID period.  
Overall, there was a deficit of 45,501 procedures during the COVID period compared to the 
monthly averages (March-May) in 2018-2019.  Cardiac catheterisation and device 
implantations were the most affected in terms of numbers (n=19,637 and n=10,453) whereas 
surgical procedures such as MVR, other valve replacement/repair, ASD/VSD repair and 
CABG were the most affected as a relative percentage difference () to previous years’ 
averages. TAVR was the least affected (-10.6%). No difference in 30-day mortality was 
observed between pre-COVID and COVID time-periods for all cardiac procedures except 
cardiac catheterisation (OR 1.25 95% confidence interval (CI) 1.07-1.47, p=0.006) and cardiac 
device implantation (OR 1.35 95% CI 1.15-1.58, p<0.001). 
Conclusion: Cardiac procedural activity has significantly declined across England during the 
COVID-19 pandemic, with a deficit in excess of 45000 procedures, without an increase in risk 
of mortality for most cardiac procedures performed during the pandemic. Major restructuring 
of cardiac services is necessary to deal with this deficit, which would inevitably impact long-





































































The COVID-19 pandemic has had a substantial influence on the provision of healthcare 
globally. This has been particularly evident in across cardiac services, given the reliance on 
multidisciplinary teams and the need for intensive care unit (ICU) bed availability.  Patients 
with cardiovascular disease (CVD) were also subject to stricter isolation measures due to their 
increased risk of COVID-related death. 1-5 While there have been multiple reports indicating a 
reduction in the volume of different cardiac procedures, these have been based on single-centre 
experiences or examination of specific procedures, 3, 6-9 rather than considering the broad 
spectrum of cardiac procedures from a national perspective. Therefore, little is known about 
the characteristics of patients undergoing procedures during the pandemic, and how these 
compare with those in the pre-COVID period. Furthermore, there is limited outcomes data for 
cardiac procedures performed prior to and during the COVID-19 pandemic. 
The present study was designed to compare procedural activity between the pre-
COVID and COVID period, as well as examine the associated 30-day mortality across cardiac 
procedures in England.  
Methods 
Data Source, Study Design and Population 
 All major cardiac and cardiothoracic inpatient and outpatient procedures performed in 
adults (aged ≥18 years) in England between 1st January and 31st May for each of the years 
2018, 2019 and 2020 were extracted from Hospital Episode Statistics (HES) (NHS Digital). 
The HES dataset collects all data on all hospital admissions, outpatient appointments and 
accident and emergency attendances in NHS hospital.10 All elective and emergent/urgent 
hospital procedures studied included cardiac catheterisation, cardiac device implantations, 



































































(CABG) surgery, surgical and transcatheter aortic valve replacement (SAVR and TAVR, 
respectively), mitral valve replacement (MVR), other valve replacement/repair, and atrioseptal 
and ventriculoseptal defects (ASD and VSD respectively) repair. Given seasonality of 
procedural activity, we only included the first five months of each calendar year. Procedures 
were excluded if there was missing data for date and/or recording of death (n=230). Patients 
who received multiple procedures (n=35,984, 9,6% of final dataset) within a 30-day period 
were excluded in the analysis of 30-day mortality, as were deaths occurring more than 30 days 
after the procedure (n=20,928).  30-day mortality was collected via record linkage with the 
Office for National Statistics (ONS) Civil Registrations of Death dataset (up to date as of 7th 
July 2020).11 The process of death certification and registration is a legal requirement in the 
United Kingdom, where a doctor who has seen the deceased within the last 14 days of life must 
complete a Medical Cause of Death Certificate unless a post-mortem examination is planned. 
International Classification of Diseases, tenth revision (ICD-10) codes were used to extract 
patient characteristics from HES, whereas OPCS Classification of Interventions and 
Procedures version 4.8 was used to identify procedures. A full list of the diagnosis codes used 
in the study is provided in Supplementary Table 1.  
Outcomes 
 The co-primary outcomes were change in proportion () of monthly procedural activity 
between 2020 and earlier years (2018-2019) as well as the 30-day mortality rate for procedures 
performed before and after the COVID-19 pandemic.  
Statistical Analysis 
We examined the characteristics of patients undergoing the most common cardiac 
procedures over two time periods: 1st January-31st May 2018 and 2019; and 1st January-29th 
February 2020 (COVID period) and 1st March-31st May 2020 (COVID period). Age was 



































































compared using the t-test. Categorical variables were summarized as percentages and analysed 
using the chi squared (X2) test or Fisher’s exact test, where appropriate, and using the Kruskal-
Wallis test for ordinal variables. Multivariable logistic regression models were fit to quantify 
the risk of 30-day mortality in the COVID period using the pre-COVID period as the reference 
category and are expressed as odds ratios (OR) with corresponding 95% confidence intervals 
(CI). Models were adjusted for age, sex, ethnicity, ST-elevation myocardial infarction 
(STEMI), non-ST-elevation acute coronary syndromes (NSTEACS), elective vs. inpatient 
admission, dyslipidaemia, smoking history, cardiac arrest, chronic heart failure, history of 
ischemic heart disease (IHD), myocardial infarction (MI), PCI, CABG surgery or 
cerebrovascular accident (CVA), atrial fibrillation (AF), ventricular tachycardia or fibrillation 
(VF/VT), dementia, chronic renal failure, hypertension, anaemia, chronic lung disease, 
diabetes mellitus, coagulopathies, liver disease, cancers, metastatic disease, peripheral vascular 
disease (PVD) and cardiogenic shock. Statistical analyses were performed using Stata 16 MP 
(College Station, TX). 
Ethical Approval 
The UK Secretary of State for Health and Social Care has issued a time limited Notice 
under Regulation 3(4) of the NHS (Control of Patient Information Regulations) 2002 (COPI) 
to share confidential patient information. The study complies with the Declaration of Helsinki. 
This work was part of a work stream endorsed by the Scientific Advisory Group for 
Emergencies (SAGE), the body responsible for ensuring timely and coordinated scientific 
advice is made available to UK government decision makers. SAGE supports UK cross-
government decisions in the Cabinet Office Briefing Room (COBR) and by NHS England, 
which oversees commissioning decisions in the NHS, and NHS Improvement, which is 
responsible for overseeing quality of care in NHS hospitals. 



































































Patient and public were not involved because this study was to analyse routinely 
collected mortality and procedural data. 
 
Results 
  A total of 374,899 cardiac procedures were performed between 1st January and 31st 
May 2018 to 2020 in England. The most commonly performed procedure was cardiac 
catheterisation (n=152,656), followed by cardiac device implantation (n=109,435), PCI 
(n=90,245), percutaneous ablation (n=22,903), CABG (n=18,030), SAVR (n=10,400), TAVR 
(n=5,664), MVR (n=4,774), other valve replacement/repair (n=1,400) and ASD/VSD repair 
(n=1,324).  
Procedural activity 
 Overall, there was little change in procedural activity per 100,000 population in January 
and February 2020 compared with the corresponding monthly averages in 2018-2019, with an 
observed increase in some procedures (TAVR:  24.6 and 32.3% respectively, other valve 
replacement/repair:  5.6 and 16.7%, ASD/VSD repair:  2.7 and 3.2%) and a decline in others 
(cardiac catheterisation:  -6.5 and -7.3%, CABG:  -4.0 and -9.1%, cardiac devices:  -8.8 
and -9.7%). (Table 1, Figure 1)  
There was a decline in numbers of all procedures performed between March and May 
2020 compared with the 2018-2019 average for these months (total deficit: 45,501 procedures) 
(Table 1).  Cardiac catheterisation and device implantations were the most affected in terms of 
numbers (n=19637 and n=10453) whereas surgical procedures such as MVR, other valve 
replacement/repair, ASD/VSD repair and CABG were the most affected as a relative 
percentage to previous years’ averages. TAVR was the least affected ( -10.6%, 116 



































































(up to  -89.7%), with the least affected procedures being cardiac device implantation ( -
52.8% to -56.8%), PCI ( -36.0 to -41.2%) and TAVR ( -18.1 to -35.4%). (Table 1)  
Patient characteristics 
 In comparison with the pre-COVID period, patients undergoing certain procedures 
(PCI, cardiac catheterisation, CABG, TAVR and SAVR) were younger, whereas those 
undergoing percutaneous ablation and cardiac device implantation were older. (Tables 2a and 
2b) Those undergoing PCI, cardiac catheterisation, MVR and CABG during the COVID period 
were more likely to be males compared to pre-COVID. Furthermore, there were fewer patients 
from Asian ethnic background during the COVID period amongst all procedural groups except 
other valve replacement/repair.  
30-day mortality 
While there was no difference in unadjusted rates of 30-day mortality for the majority 
of procedures performed in the pre-COVID and COVID time periods (Table 3), 30-day 
mortality was higher during the COVID period for patients undergoing cardiac catheterisation 
(1.6% vs. 1.1%, p<0.001), ASD/VSD repair (9.1% vs. 1.4%, p=0.002), percutaneous ablation 
(0.5% vs. 0.2%, p=0.037) and cardiac device implantation (2.0% vs. 1.4%, p<0.001). 
(Supplementary Figure 1). 
After adjustment for baseline differences, there was no difference in 30-day mortality 
between pre-COVID and COVID time periods, except in those undergoing cardiac 
catheterisation and cardiac device implantation, who had increased odds of 30-day mortality 
(OR 1.25 95% CI 1.07, 1.47, p=0.006 and OR 1.35 95% CI 1.15, 1.58, p<0.001 respectively). 
(Table 4, Figure 2) 
Discussion 
 We present the first study to examine the impact of COVID-19 on procedural activity 



































































study presents several important findings. First, we observe a substantial decline in all cardiac 
procedures performed between March and May 2020 compared to the same time period in 
earlier years (2018-2019), with certain procedures being more affected than others. We report 
a total deficit of more than 45,000 cardiac procedures over the COVID period (March-May 
2020) compared with previous years. Second, we report minor age and ethnic differences in 
patient characteristics for the majority of cardiac procedures performed before and after the 
COVID-19 pandemic. Finally, we show that there was no difference in 30-day mortality 
between the pre-COVID and COVID periods for the majority of procedures, except in cardiac 
catheterisation and device implantation procedural groups that were associated with increased 
mortality.  
 The COVID-19 pandemic has led to substantial operational changes in healthcare 
delivery, especially among procedural specialties. Many professional societies recommended 
cancellation of elective procedures particularly in high-risk patients due to their increased risk 
of contracting COVID-19 and their increased risk of mortality, mainly due to factors such as 
prolonged hospital admission, the invasive nature of certain procedures, aerosol-generating 
nature of procedures, and the potential need for ICU resources that have been otherwise 
prioritised for COVID-19 cases. 1, 2, 4, 12-18 As such, procedural activity has reportedly declined 
in many institutions. 3, 4, 19 Although some studies or surveys have examined procedural activity 
in the COVID era, these mainly included specific centres (e.g. large tertiary facilities) or 
healthcare systems (e.g. Veterans Affairs (VA) only), early phases of the pandemic (e.g. up to 
April 2020), or specific procedures (e.g. PCI) without comparison between different procedure 
types. 4, 7, 8, 19, 20 It is therefore, unclear which procedures were most affected nationally, the 
implications of such changes in activity and whether the outcomes of those who underwent 




































































Waldo et al. reported a reduction in both elective and urgent PCI procedures in the VA 
healthcare system between 1st March and 27th June 2020 compared with the same time period 
in 2019 (3,859 to 2,192).6 While these findings are insightful, they were based on a relatively 
small number of PCI procedures from a single healthcare system that do not reflect national 
practice, and do not inform us of differences in outcomes between the two time periods. 
Another study by Lazaros et al. demonstrated a decline in cardiac surgery procedure activity 
in 2 large volume hospitals in Greece between 12th March and 7th May 2020 compared with 
the same time period in 2019 (246 vs. 84 procedures), especially for elective cases, with a 
relative rise in emergent procedures.8 However, their analysis was based on a small number of 
very specific procedure types, and did not look at postoperative outcomes for these time 
periods. Our findings demonstrate a substantial decline all cardiac procedural activity across 
England during the COVID period, even before the start of national lockdown (23rd March 
2020). The greatest decline in procedure rates was observed amongst surgical procedures 
including MVR, other valve replacement/repair, ASD/VSD repair and CABG, whereas cardiac 
catheterisation and device implantations were the most affected in terms of absolute numbers. 
Although there were certain age and ethnic differences between patients undergoing 
certain procedures in the pre-COVID and COVID time periods, the majority of characteristics 
were largely similar, suggesting that all individuals were affected. We found no difference in 
30-day mortality between COVID and pre-COVID time periods for all cardiac procedures, 
except cardiac catheterisation and device implantations that were associated with increased 
odds of 30-day mortality, even after adjustment for baseline differences. The increased 
mortality amongst cardiac catheterisation and device implantation procedures could be due to 
residual confoundment, given that procedural characteristics were not captured in HES and, 
therefore, not adjusted for. This may be relevant for where higher risk patients prior to COVID 



































































CT, and during the COVID period, such patients were managed with an invasive approach to 
avoid close proximity to patients potentially infected with COVID-19 undergoing CT 
examinations. Similarly, only the most urgent device implantations are likely to have been 
performed during the COVID period, reflecting a higher risk cohort. Further work is required 
to define the cause of the increases in mortality in these patient groups, particularly whether 
the deaths were related to procedural complications or COVID-19 in the community.   
Our findings raise important questions regarding the outcomes of patients whose 
interventions were deferred, especially those who are more frail or with a greater burden of 
comorbidities. Although difficult to quantify, the indirect burden of COVID-19 on morbidity 
and mortality of patients with cardiovascular disease whose interventions were deferred may 
exceed the direct effect of the infection in terms of mortality. For example, the one-year 
mortality of untreated symptomatic severe aortic stenosis (AS) is as high as 44% 21, 22 Similarly, 
severe untreated mitral stenosis is associated with high morbidity and mortality.23 Therefore, 
timely interventions for such patients are crucial, and without a major restructure of health 
services to deal with the current backlog/deficit in procedural activity, which is quite significant 
in our national cohort, we are likely to observe an impact on their long-term morbidity and 
mortality. There has been limited guidance on the safe reintroduction of cardiovascular services 
during the pandemic, and this was primarily based on expert opinion. 16 24 Guidance from the 
North American Society Leadership recommend measures such as pre-procedural physical 
distancing wherever possible, COVID-19 screening, and availability of personal protective 
equipment (PPE) as well as close collaboration with regional public health officials. 24 
Prachand et al. proposed the medically-necessary time-sensitive (MeNTS) scoring system, 
based on 21 factors (patient, procedural, and disease-related), as a means of prioritising time-
sensitive procedures while taking into account resource limitations during the COVID-19 



































































allocation of equal weighting to all 21 factors and lack of consideration of the patient’s COVID 
status, the MeNTS score highlights the need for more refined scoring systems to objectively 
assess patient risk and the availability of resources and safely resume elective as well as semi-
urgent procedural activity. Furthermore, several contingency measures could be employed to 
deal with the backlog in waiting lists such as seven-day working patterns in major centres, the 
collaboration with private healthcare institutions for bed availability, as well as recently retired 
operators who may be willing to temporarily return to practice. This is even more crucial in the 
event of further resurgence of COVID-19 outbreaks that would further increase the pressure 
on healthcare systems and continually growing waiting lists.  
Limitations 
There are several limitations to the present study. First, the observational nature of our 
analysis means that the observed associations do not necessarily infer causality. Second, while 
HES captures a significant amount of patient characteristics, factors such as the overall 
comorbid burden and frailty status cannot be objectively fully assessed using administrative 
data. Furthermore, certain procedural characteristics as well as pharmacological data were not 
available in HES, and therefore were not adjusted for. Finally, while we have demonstrated 
similar 30-day mortality in the pre-COVID and COVID eras for most procedures, these 
outcomes may differ significantly on longer follow up.  
Conclusions 
 The COVID-19 pandemic resulted in a significant decline of all major cardiac 
procedural activity across England, with the most affected procedures being CABG, mitral and 
other valvular repairs/replacements, ASD/VSD repair as well as cardiac catheterisation and 
device implantations. Adjusted 30-day mortality was similar in the pre-COVID and COVID 



































































Major operational changes are warranted to deal with the deficit in procedural activity and 
anticipated growth in waiting lists that could impact longer-term morbidity and mortality.  
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Figures captions and legends: 
Figure 1. Trend of procedural activity (January-May) over the study years 
 
Legend: ASD/VSD: atrioseptal and ventriculoseptal defect; CABG: coronary artery bypass grafting; MVR: 
mitral valve replacement; PCI: percutaneous coronary intervention; SAVR: surgical aortic valve replacement; 
TAVR: transcatheter aortic valve replacement 
 
Figure 2. Adjusted odds of 30-day mortality according to procedure typea 
 
Legend: ASD/VSD: atrioseptal and ventriculoseptal defect; CABG: coronary artery bypass grafting; MVR: 
mitral valve replacement; PCI: percutaneous coronary intervention; SAVR: surgical aortic valve replacement; 
TAVR: transcatheter aortic valve replacement 
a reference category is January-May for years 2018 and 2019, and January-February 2020 
b Perfect predictor variable 













































































































































































































Table 1. Cardiac procedural volumes (January-May) according to time period 
 Year 
January 
















n (per 100,000) 
% 
changeb 
Total deficit in 
March-May 




2018-2019a 12139 (20.66)  11290 (19.22)  11768 (20.03)  11736 (19.98)  12571 (21.4)   
2020 11313 (19.03) -6.5 10335 (17.39) -7.3 7652 (12.87) -34.3 3066 (5.16) -73.1 4500 (7.57) -62.8 19637 (56.3) 
PCI 
2018-2019a 6531 (11.12)  5903 (10.05)  6693 (11.39)  6501 (11.07)  6720 (11.44)   
2020 6551 (11.02) -0.9 5982 (10.06) -0.9 5299 (8.91) -20.6 3763 (6.33) -41.2 4311 (7.25) -36.0 6257 (31.9) 
CABG 
2018-2019a 1413 (2.41)  1367 (2.33)  1376 (2.34)  1451 (2.47)  1531 (2.61)   
2020 1342 (2.26) -9.1 1284 (2.16) -4.0 802 (1.35) -43.6 245 (0.41) -82.4 323 (0.54) -78.0 2860 (67.6) 
ASD/VSD 
Repair 
2018-2019a 105 (0.18)  94 (0.16)  98 (0.17)  107 (0.18)  113 (0.19)   
2020 114 (0.19) 2.7 96 (0.16) 3.2 58 (0.1) -44.4 20 (0.03) -83.8 16 (0.03) -81.8 217 (69.8) 
TAVR 
2018-2019a 350 (0.6)  306 (0.52)  317 (0.54)  369 (0.63)  341 (0.58)   
2020 483 (0.81) 24.6 466 (0.78) 32.2 447 (0.75) 20.0 251 (0.42) -35.4 308 (0.52) -18.1 119 (10.6) 
SAVR 
2018-2019a 858 (1.46)  771 (1.31)  757 (1.29)  805 (1.37)  882 (1.5)   
2020 754 (1.27) -11.8 698 (1.17) -12.0 464 (0.78) -43.3 187 (0.31) -76.0 224 (0.38) -73.0 1527 (63.6) 
MVR 
2018-2019a 396 (0.67)  341 (0.58)  326 (0.55)  416 (0.71)  446 (0.76)   
2020 377 (0.63) -1.6 337 (0.57) 0.9 217 (0.37) -38.3 58 (0.1) -85.1 63 (0.11) -83.8 810 (70.6) 
Other valves 
2018-2019a 112 (0.19)  98 (0.17)  90 (0.15)  128 (0.22)  145 (0.25)   
2020 127 (0.21) 16.7 115 (0.19) 5.6 51 (0.09) -45.5 15 (0.03) -85.4 12 (0.02) -89.7 252 (76.4) 
Percutaneous 
Ablation 
2018-2019a 1777 (3.02)  1657 (2.82)  1741 (2.96)  1671 (2.84)  1845 (3.14)   
2020 1894 (3.19) 0.5 1695 (2.85) 3.8 1199 (2.02) -32.0 190 (0.32) -88.8 476 (0.80) -73.9 3369 (64.4) 
Cardiac 
Devices 
2018-2019a 8700 (14.81)  8026 (13.66)  8180 (13.92)  8300 (14.13)  8695 (14.8)   
2020 7708 (12.97) -9.7 7081 (11.91) -8.8 6469 (10.88) -21.4 3752 (6.31) -52.8 3585 (6.03) -56.8 10453 (43.1) 
a average number of procedures over 2018 and 2019 
b % change between 2018-2019 average and 2020, based on procedure frequency per 100,000 population 
 











































































Males 64.5 65.9 <0.001 74.6 75.9 0.002 54.5 57.7 0.065 61.2 62.5 0.305 66.5 67.2 0.130 
Ethnicity   <0.001   <0.001   <0.001   0.916   <0.001 
White 76.5 76.8  73.3 72.1  76.6 69.3  72.6 73.1  80.7 82.0  
Asian 6.6 5.3  7.7 6.8  2.2 1.7  2.2 2.0  3.8 2.8  
Black 1.6 1.3  1.0 0.9  0.6 0.3  1.0 1.0  1.3 1.1  
Other 15.3 16.6  17.9 20.2  20.6 28.7  24.2 23.8  14.2 14.2  
STEMI 3.0 4.8 <0.001 31.1 37.8 <0.001 0.1 0.0 0.255 0.1 0.1 0.695 1.6 1.5 0.321 
NSTEACS 15.7 19.3 <0.001 32.2 34.3 <0.001 1.2 1.3 0.813 0.2 0.3 0.539 5.3 3.8 <0.001 
Dyslipidemia 33.6 30.8 <0.001 38.7 35.3 <0.001 25.6 23.1 0.096 12.2 11.2 0.199 20.9 16.4 <0.001 
Cardiac arrest 0.2 0.3 0.016 0.7 0.6 0.150 0.7 0.5 0.542 0.0 0.0 0.346 0.5 0.5 0.568 
Heart failure 15.4 15.4 0.818 15.3 15.8 0.053 27.7 24.4 0.024 13.3 18.0 <0.001 25.2 25.9 0.08 
VF/VT 1.6 2.1 <0.001 2.7 3.6 <0.001 1.7 1.9 0.635 5.7 6.4 0.186 4.4 5.3 <0.001 
AF 3.4 3.9 0.002 2.1 2.2 0.203 6.6 5.5 0.194 25.5 23.5 0.055 6.8 7.5 0.006 
History of IHD 14.3 15.2 0.004 17.1 17.6 0.178 15.9 11.8 0.001 6.4 8.5 0.001 13.9 15.2 <0.001 
Previous 
CABG 
5.4 4.8 0.003 6.1 4.8 <0.001 12.0 7.9 <0.001 3.3 3.8 0.237 5.6 5.7 0.561 
Dementia 0.4 0.3 0.259 0.5 0.4 0.214 1.5 0.6 0.021 0.2 0.1 0.214 1.7 1.8 0.394 
Chronic renal 
failure 
8.1 7.1 <0.001 7.5 6.6 <0.001 23.9 18.1 <0.001 3.6 4.9 0.003 11.0 11.4 0.155 
Hypertension 54.8 53.9 0.048 55.2 52.9 <0.001 61.2 58.2 0.076 31.7 32.3 0.604 47.0 46.2 0.079 
Anemias 2.1 1.8 0.05 2.0 1.6 0.009 10.3 8.3 0.063 1.0 0.9 0.79 4.9 4.0 0 
Chronic lung 
disease 
17.9 18.0 0.700 15.2 15.0 0.481 23.3 20.5 0.053 13.0 13.0 0.929 14.0 14.4 0.194 
Diabetes 23.9 22.7 0.002 25.1 24.1 0.008 26.0 20.9 0.001 10.0 10.7 0.378 20.0 19.8 0.49 
Coagulopathies 0.6 0.5 0.191 0.5 0.5 0.878 2.4 2.6 0.675 0.5 0.3 0.199 1.6 1.1 <0.001 


















































0.3 0.4 0.021 0.3 0.3 0.124 0.5 0.6 0.611 0.1 0.1 0.979 0.3 0.4 0.284 
PVD 4.4 4.0 0.064 4.3 4.3 0.705 12.8 10.8 0.094 1.9 1.2 0.052 4.5 4.1 0.028 
Cardiogenic 
shock 
0.3 0.3 0.661 1.4 1.3 0.264 0.4 0.2 0.408 0.1 0.1 0.871 0.4 0.5 0.473 
Cancers 1.7 1.7 0.651 1.8 1.5 0.056 3.5 4.3 0.234 0.7 0.9 0.495 2.1 2.2 0.236 
a January-May for years 2018 and 2019, and January-February 2020 














































































Males 67.6 68.7 0.521 61.1 67.2 0.031 54.7 60.8 0.300 47.2 53.8 0.221 81.9 85.0 0.005 
Ethnicity   0.016   0.155   0.037   0.814   <0.001 
White 73.8 73.0  70.5 69.2  70.7 60.3  64.0 63.8  69.0 70.1  
Asian 2.9 1.3  4.6 2.4  4.7 5.1  5.4 3.2  7.2 4.1  
Black 1.0 0.8  1.8 2.1  1.4 5.1  2.0 2.1  0.7 1.1  
Other 22.3 24.9  23.0 26.3  23.2 29.5  28.7 30.9  23.1 24.7  
STEMI 0.4 1.0 0.005 1.0 0.9 0.793 0.2 1.3 0.09 3.4 8.5 0.012 4.7 5.5 0.199 
NSTEACS 3.9 4.2 0.649 2.6 3.0 0.684 0.6 1.3 0.467 1.3 3.2 0.137 28.4 32.4 0.002 
Dyslipidemia 35.6 31.2 0.008 23.4 19.2 0.077 18.6 21.8 0.484 12.0 8.5 0.307 55.6 54.2 0.311 
Cardiac arrest 0.6 0.7 0.842 0.5 0.0 0.185 0.9 0.0 0.398 0.2 1.1 0.077 0.4 0.4 0.670 
Heart failure 22.0 24.2 0.103 32.2 36.4 0.070 35.1 37.2 0.678 15.3 27.7 0.003 19.7 22.4 0.016 
VF/VT 3.0 3.4 0.506 3.5 8.0 <0.001 4.1 10.3 0.01 3.1 5.3 0.240 2.7 2.7 0.999 
AF 6.2 5.9 0.805 8.9 8.9 0.992 7.3 7.7 0.887 5.3 7.4 0.373 4.0 3.6 0.486 
History of IHD 8.9 9.3 0.741 6.9 6.5 0.762 3.9 3.8 0.969 3.1 6.4 0.086 23.8 28.6 <0.001 
Previous 
CABG 
1.1 1.4 0.451 1.9 2.7 0.324 1.4 1.3 0.953 0.4 1.1 0.360 1.6 1.4 0.478 
Dementia 0.2 0.0 0.155 0.2 0.0 0.465 0.2 0.0 0.731 0.1 0.0 0.782 0.2 0.1 0.339 
Chronic renal 
failure 
10.1 9.0 0.303 11.0 12.7 0.346 12.4 10.3 0.574 4.7 6.4 0.468 9.8 9.5 0.745 
Hypertension 60.5 61.0 0.78 47.1 44.4 0.327 39.0 41.0 0.726 26.3 26.6 0.943 70.3 74.9 <0.001 
Anemias 11.9 13.1 0.261 11.8 12.1 0.862 12.0 12.8 0.834 5.5 7.4 0.438 11.3 12.8 0.104 
Chronic lung 
disease 
16.5 19.2 0.043 16.9 15.7 0.554 14.5 14.1 0.918 11.4 9.6 0.593 15.4 16.9 0.138 
Diabetes 19.3 18.1 0.365 10.5 9.2 0.446 9.4 10.3 0.797 6.9 11.7 0.084 31.5 30.9 0.659 
















































Liver disease 2.6 2.2 0.482 2.9 4.4 0.107 4.4 7.7 0.174 2.4 2.1 0.887 1.9 1.7 0.519 
Metastatic 
disease 
0.2 0.1 0.621 0.2 0.6 0.195 1.7 3.8 0.157 0.3 0.0 0.580 0.1 0.1 0.892 
PVD 10.6 11.2 0.557 5.2 4.4 0.560 4.5 2.6 0.410 2.7 2.1 0.746 9.9 10.0 0.898 
Cardiogenic 
shock 
0.7 1.1 0.093 1.1 3.6 <0.001 1.1 2.6 0.224 1.7 3.2 0.299 0.6 1.1 0.049 
Cancers 1.8 1.8 0.985 1.4 1.5 0.957 2.2 5.1 0.097 0.4 0.0 0.536 1.5 1.1 0.219 
a January-May for years 2018 and 2019, and January-February 2020 

















1.1% 1.6% 1.2% <0.001 
PCI 2.7% 2.8% 2.7% 0.481 
CABG 1.1% 1.8% 1.1% 0.328 
ASD/VSD Repair 1.4% 9.1% 1.9% 0.002 
TAVR 2.4% 2.1% 2.3% 0.687 
SAVR 4.4% 6.9% 4.9% 0.326 
MVR 6.2% 3.3% 5.8% 0.532 
Other valves 2.3% 0%b 2.0% 0.799 
Percutaneous 
Ablation 
0.2% 0.5% 0.2% 0.037 
Cardiac Devices 1.4% 2.0% 1.5% <0.001 
a Included months are January through May for 2018 and 2019;  
b no deaths occurred 
 
Table 4. Adjusted odds ratios (OR) of 30-day mortality during March-May 2020 according 
to procedure typea 
 OR [95% confidence interval] p-value 
Cardiac catheterisation 1.25 [1.07, 1.47] 0.006 
PCI 1.02 [0.89, 1.16] 0.829 
CABG 2.77 [0.85, 9.03] 0.090 
ASD/VSD Repair b b 
TAVR 0.85 [0.39, 1.84] 0.682 
SAVR 1.64 [0.49, 5.40] 0.420 
MVR b b 
Other valve repair/replacement c c 
Percutaneous Ablation 1.71 [0.73, 3.98] 0.215 
Cardiac Devices 1.35 [1.15, 1.58] <0.001 
a reference category is January-May for years 2018 and 2019, and January-February 2020 
b Perfect predictor variable 
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- Supplementary Figure 1. Crude rates of 30-day mortality according to procedure type 





Supplementary Figure 1. Crude rates of 30-day mortality according to procedure type 
 
 
ASD/VSD: atrioseptal and ventriculoseptal defect; CABG: coronary artery bypass grafting; MVR: mitral valve 
replacement; PCI: percutaneous coronary intervention; SAVR: surgical aortic valve replacement; TAVR: 



























Supplementary Table 1. Search codes 
Variable Source Code 
Diagnoses   
STEMI ICD-10 I210* I211* I212* I213 
NSTEACS ICD-10 I214 I219 I200 (UA) 
Dyslipidaemia ICD-10 E78* 
Smoker ICD-10 Z720 
Cardiac arrest ICD-10 
I462 (due to cardiac condition); I468 and I469 (due 
to non-cardiac condition) 
Heart Failure ICD-10 I50* Cardiomyopathy: I42* 
AF ICD-10 I4891 I4820-21 I4811 I4819 I480 
History of IHD ICD-10 
I2510 I25110 I25111 I25118 I25119 I257* I258* 
I259* 
Dementia (Presenile Senile 
Vascular and Alzheimer’s) 
ICD-10 F01* F02* F03* 
Chronic renal failure ICD-10 N18* 
Hypertension ICD-10 I10* 
Anaemia ICD-10 D62* D63* D64* 
Chronic Lung Disease 
(including bronchitis COPD, 
asthma and bronchiectasis) 
ICD-10 J41* J42* J43* J44* J45* J47* 
Diabetes ICD-10 E08* E09* E10* E11* E13* 
Coagulopathies ICD-10 D65 D66 D67 D68* D69* 
Liver disease ICD-10 K70* K721* K729* K73* K74* K75* K76* K77* 
Metastatic disease ICD-10 C77* C78* C79* R180* C7B* 
PVD ICD-10 I73* 
Valvular heart disease ICD-10 I34* I35* I36* I37* 
Cardiogenic shock ICD-10 R570 
In-hospital procedures   
CABG OPCS K40-K46 
PCI OPCS K75* K49* 
Cardiac catheterisation OPCS K63* K65* 
Percutaneous Ablation OPCS K57* K621 K622 K623 
Cardiac Devices OPCS K59-K61 K72-K74 
ASD/VSD repair OPCS K09/K16 
TAVR OPCS 
Additional codes: Y494 Y791 Y792 Y793 Y794 
Y798 
SAVR/Repair OPCS K26* K302 K312 K322 K373 K374 
MVR/Repair OPCS K25* K301 K311 K321 K341 K383 
Other valvular replacements 
and repairs (including 
tricuspid and pulmonary) 
OPCS 
K27* K303 K313 K323 K342 K345 K28* K304 
K314 K324 K346 K29* 
ICD-10: International Classification of Diseases Tenth Edition Clinical Modification; OPCS: OPCS Classification of 
Interventions and Procedures version 4.8 
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